Clinical trials
High Grade Serous Ovarian Cancer clinical trials
Below are recruiting high grade serous ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 155 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04710797Recruiting
Lymph node surgery for early-stage ovarian cancer
This trial studies whether removing (dissecting) lymph nodes during surgery can improve care for people with early-stage ovarian cancer that still needs chemotherapy. You may be eligible if you have certain ovarian cancer types and your scans and surgery do not show clearly suspicious lymph nodes.
Guangzhou, GuangdongAges 18–70 - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT05255471RecruitingPhase 3
Olaparib after surgery for recurrent ovarian cancer
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
NaplesAges 18 years+ - NCT05961124RecruitingPhase 2
Lower-dose niraparib to reduce interruptions in ovarian maintenance
This trial tests whether a different starting dose (and adjustments) of niraparib can help people with advanced ovarian (or related) cancer stay on treatment without as many dose interruptions. It’s designed for people who have already finished first-line chemotherapy and whose cancer responded.
Toronto, OntarioAges 18 years+ - NCT06084416RecruitingPhase 1
Pill study for advanced ovarian cancer that resists chemo
This trial tests an experimental drug called sovilnesib (taken as a pill) for people with advanced ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum chemo. The goal is to see if this drug can shrink or slow the cancer.
Birmingham, AlabamaAges 18 years+ - NCT05652283RecruitingPhase 2
Combination treatment before surgery for advanced ovarian cancer
This trial tests two oral medications, pamiparib and surufatinib, given before surgery to shrink advanced ovarian cancer. The goal is to make surgery more successful and potentially improve outcomes for patients who cannot have surgery right away.
Hefei, AnhuiAges 18 years+ - NCT05080556RecruitingPhase 2
Adaptive chemotherapy for ovarian cancer after platinum and PARP
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
LondonAges 18 years+ - NCT06395844RecruitingPhase 1/Phase 2
NK cell therapy for advanced ovarian cancer
This trial tests a new therapy that uses your own natural killer (NK) cells, modified to better fight cancer and injected directly into your abdomen. It's for people with advanced ovarian cancer who cannot have surgery or whose tumor cannot be fully removed.
Hefei, AnhuiAges 18–70 - NCT06216496Recruiting
Amino acid changes in advanced ovarian cancer
This study looks at how ovarian cancer changes the body's use of amino acids, which are building blocks of proteins. It may help find new ways to monitor or treat the disease.
La TroncheAges 40–70 - NCT07821879Recruiting
Early ovarian cancer detection via cervical smear testing
This study looks at whether a standard cervical smear test can help find ovarian cancer earlier. The test searches for genetic changes linked to high-grade serous ovarian cancer in cells collected from the cervix, possibly enabling earlier diagnosis.
ToulouseAges 18 years+ - NCT07776691RecruitingPhase 3
Study of Raludotatug Deruxtecan for Advanced Ovarian Cancer
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07783022Recruiting
Real-world study of niraparib for ovarian cancer after initial treatment
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
ShanghaiAges 18 years+ - NCT07772869Recruiting
Uterine washing test to detect ovarian cancer risk
This study is testing a new way to find ovarian cancer early. It uses a gentle washing of the uterus (like a Pap test) to collect cells and look for signs of cancer in women who are at high risk because of a BRCA gene mutation. The goal is to see if this method can detect cancer before it spreads, which might help save more lives.
Seattle, WashingtonAges 18 years+ - NCT07736937RecruitingPhase 1/Phase 2
Study of TUB-040 with Standard Drugs for Ovarian Cancer
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07714668RecruitingPhase 2
Combination therapy for recurrent ovarian cancer
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06640348Recruiting
New blood test for ovarian cancer screening
This study uses a special blood test (SERS) to find tiny signs of ovarian cancer in the blood. It may help diagnose ovarian cancer earlier or more accurately.
Hefei, AnhuiAges 18–70 - NCT07665515RecruitingPhase 1
Testing a cancer vaccine in maintenance for advanced ovarian cancer
This trial tests a vaccine called CryptiVax-1001 for people with advanced ovarian cancer who have finished first-line chemotherapy and are in remission, as maintenance therapy. The goal is to see if the vaccine can help keep the cancer from coming back.
CambridgeAges 18 years+ - NCT06437353RecruitingPhase 2
Surufatinib combo for first-line and maintenance in high-risk ovarian cancer
This trial tests a combination of drugs (Surufatinib with carboplatin/paclitaxel) as first treatment for high-risk ovarian cancer, followed by a different combination (Surufatinib with olaparib) to keep the cancer from coming back. It aims to see if these targeted therapies work better than the standard approach.
Hefei, AnhuiAges 18–75 - NCT07564141RecruitingPhase 3
New Drug for Recurrent Ovarian Cancer After Chemotherapy
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
Duarte, CaliforniaAges 18 years+ - NCT06735326RecruitingPhase 2
Fluzoparib and Bevacizumab Before Surgery for Advanced Ovarian Cancer
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
Jinan, ShandongAges 18 years+ - NCT07556562Recruiting
Early ovarian cancer detection through Pap test DNA analysis
This study tests whether DNA found in routine Pap smears can help detect ovarian cancer early in people at high genetic risk. Participants have inherited gene mutations that increase ovarian cancer risk and are considering preventive surgery.
Roma, RomaAges 18 years+ - NCT07546500RecruitingPhase 3
Azenosertib versus chemotherapy for advanced ovarian cancer
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
Phoenix, ArizonaAges 18 years+ - NCT07544030RecruitingPhase 3
PIPAC chemotherapy for advanced ovarian cancer
This study tests a new way to deliver chemotherapy directly into the abdomen (called PIPAC) for women with advanced ovarian cancer who cannot have surgery to remove all tumors. The goal is to see if this approach is safe and helps slow cancer growth.
Changchun, JilinAges 18–70 - NCT07504588RecruitingPhase 2
Comparing two drug combinations for recurrent ovarian cancer after PARP inhibitor treatment
This trial tests whether a new drug combination (sacituzumab govitecan plus bevacizumab) works better than the usual chemotherapy for ovarian cancer that has come back after platinum treatment and PARP inhibitor maintenance. It may offer a new option for people with certain genetic markers (BRCA mutations or HRD).
Fayetteville, ArkansasAges 18 years+
Hear when a new High Grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
High Grade Serous Ovarian Cancer trials by city
Studies with a site in or near these metro areas.
High Grade Serous Ovarian Cancer trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for high grade serous ovarian cancer?
- Yes. Clin2 currently lists 155 recruiting high grade serous ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high grade serous ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high grade serous ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.